DPP-4 inhibitors in the treatment of type 2 diabetes. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Biochemical Pharmacology Year : 2012

DPP-4 inhibitors in the treatment of type 2 diabetes.


Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 'discovery' of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or gliptins) with different chemical structures are now available. These agents inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a ≥ 80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, and significantly reducing HbA1c generally by -0.7 to 0.8% as well as fasting and post-prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycaemic episodes. Although different by their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently available have proven similar glucose lowering efficacy.
Fichier principal
Vignette du fichier
Duez_et_al._DPP4inhibitors_MStext.pdf (254.9 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00659269 , version 1 (12-01-2012)



Hélène Duez, Bertrand Cariou, Bart Staels. DPP-4 inhibitors in the treatment of type 2 diabetes.. Biochemical Pharmacology, 2012, 83 (7), pp.823-32. ⟨10.1016/j.bcp.2011.11.028⟩. ⟨inserm-00659269⟩
376 View
2965 Download



Gmail Facebook Twitter LinkedIn More